{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:54:40Z","timestamp":1790319280994,"version":"4.1.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>The need for predictive biomarkers that can accurately predict patients who will respond to immune checkpoint inhibitor (ICI) immunotherapies remains a clinically unmet need. The majority of research efforts have focused on expression of immune-related markers on the tumour and its associated tumour microenvironment (TME). However, immune response to tumour neoantigens starts at the regional lymph nodes, where antigen presentation takes place and is regulated by multiple cell types and mechanisms. Knowledge of the immunological responses in bystander lymphoid organs following ICI therapies and their association with changes in the TME, could prove to be a valuable component in understanding the treatment response to these agents. Here, we review the emerging data on assessment of immunological responses within regional lymph nodes as predictive biomarkers for immunotherapies.<\/jats:p>","DOI":"10.3389\/fmolb.2021.674558","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T04:59:21Z","timestamp":1621832361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response"],"prefix":"10.3389","volume":"8","author":[{"given":"Emily F.","family":"Goode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia T.","family":"Roussos Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s41467-018-04524-x","article-title":"Induction of Anergic or Regulatory Tumor-specific CD4(+) T Cells in the Tumor-Draining Lymph Node","volume":"9","author":"Alonso","year":"2018","journal-title":"Nat. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as First-Line Treatment in Cisplatin-Ineligible Patients with Locally Advanced and Metastatic Urothelial Carcinoma: a Single-Arm, Multicentre, Phase 2 Trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/nejmoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-small-cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/0008-5472.can-05-2246","article-title":"An Essential Role of Antigen-Presenting cell\/T-Helper Type 1 Cell-Cell Interactions in Draining Lymph Node during Complete Eradication of Class II-Negative Tumor Tissue by T-Helper Type 1 Cell Therapy","volume":"66","author":"Chamoto","year":"2006","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"E761","DOI":"10.1073\/pnas.1620433114","article-title":"Mitochondrial Activation Chemicals Synergize with Surface Receptor PD-1 Blockade for T Cell-dependent Antitumor Activity","volume":"114","author":"Chamoto","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: the Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/pd-L1-Checkpoint Restrains T Cell Immunity in Tumor-Draining Lymph Nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clim.2017.10.002","article-title":"Non-progressing Cancer Patients Have Persistent B Cell Responses Expressing Shared Antibody Paratopes that Target Public Tumor Antigens","volume":"187","author":"DeFalco","year":"2018","journal-title":"Clin. Immunol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining Lymph Nodes Are Pivotal in PD-1\/pd-L1 Checkpoint Therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non-small-cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-020-00743-4","article-title":"MHC-I Genotype and Tumor Mutational Burden Predict Response to Immunotherapy","volume":"12","author":"Goodman","year":"2020","journal-title":"Genome Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-1 Ligand Expression, and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.4049\/jimmunol.177.9.6081","article-title":"Incomplete Differentiation of Antigen-specific CD8 T Cells in Tumor-Draining Lymph Nodes","volume":"177","author":"Hargadon","year":"2006","journal-title":"J. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/nejmoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.3389\/fimmu.2019.03074","article-title":"Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model","volume":"10","author":"Hope","year":"2019","journal-title":"Front. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.15252\/emmm.201606914","article-title":"TGF\u2010\u03b21 Secreted by Tregs in Lymph Nodes Promotes Breast Cancer Malignancy via Up\u2010regulation of IL\u201017RB","volume":"9","author":"Huang","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1371\/journal.pmed.0020284","article-title":"Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-free Survival in Breast Cancer","volume":"2","author":"Kohrt","year":"2005","journal-title":"Plos Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"39247","DOI":"10.1038\/srep39247","article-title":"Prognostic Value of Circulating Regulatory T Cell Subsets in Untreated Non-small Cell Lung Cancer Patients","volume":"6","author":"Kotsakis","year":"2016","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/nejmoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.cd-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving Insights into the Mechanisms of Toxicity Associated with Immune Checkpoint Inhibitor Therapy","volume":"86","author":"Mangan","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/jci80005","article-title":"Myeloid-derived Suppressor Cells in the Tumor Microenvironment: Expect the Unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Invest."},{"key":"B31","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.4049\/jimmunol.162.10.5838","article-title":"Tumor Antigens Are Constitutively Presented in the Draining Lymph Nodes","volume":"162","author":"Marzo","year":"1999","journal-title":"J. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.3747\/co.27.5549","article-title":"Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer","volume":"27","author":"Meyers","year":"2020","journal-title":"Curr. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1600-065x.2006.00444.x","article-title":"The Tumor-Draining Lymph Node as an Immune-Privileged Site","volume":"213","author":"Munn","year":"2006","journal-title":"Immunol. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41467-020-17046-2","article-title":"Tumor Invasion in Draining Lymph Nodes Is Associated with Treg Accumulation in Breast Cancer Patients","volume":"11","author":"Nunez","year":"2020","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B Cells Are Associated with Survival and Immunotherapy Response in Sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"584423","DOI":"10.3389\/fimmu.2020.584423","article-title":"Tumor Infiltrating Effector Memory Antigen-specific CD8(+) T Cells Predict Response to Immune Checkpoint Therapy","volume":"11","author":"Principe","year":"2020","journal-title":"Front. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-small-cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"Tumor Progression Can Occur Despite the Induction of Very High Levels of Self\/tumor Antigen-specific CD8+ T Cells in Patients with Melanoma","volume":"175","author":"Rosenberg","year":"2005","journal-title":"J. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s1470-2045(19)30689-8","article-title":"Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s1470-2045(16)30066-3","article-title":"Safety and Clinical Activity of Pembrolizumab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-012): an Open-Label, Multicentre, Phase 1b Trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"118117","DOI":"10.1016\/j.lfs.2020.118117","article-title":"The Balance of Regulatory and Stimulatory B Cell Subsets in Breast Cancer Draining Lymph Nodes Correlates with Tumor Prognostic Factors","volume":"257","author":"Shariati","year":"2020","journal-title":"Life Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1158\/2326-6066.cir-14-0165","article-title":"Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3\/CD141+ Dendritic Cells and Enhanced Cross-Presentation","volume":"3","author":"Sluijter","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic Immunity Is Required for Effective Cancer Immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signaling"},{"key":"B49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12307-012-0126-7","article-title":"Tumor Microenvironment and Myeloid-Derived Suppressor Cells","volume":"6","author":"Umansky","year":"2013","journal-title":"Cancer Microenvironment"},{"key":"B51","doi-asserted-by":"publisher","first-page":"00110-2016","DOI":"10.1183\/23120541.00110-2016","article-title":"High PD-1 Expression on Regulatory and Effector T-Cells in Lung Cancer Draining Lymph Nodes","volume":"3","author":"van de Ven","year":"2017","journal-title":"ERJ Open Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.4049\/jimmunol.181.5.3291","article-title":"Tumor-Induced CD11b+Gr-1+Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes","volume":"181","author":"Watanabe","year":"2008","journal-title":"J. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/jco.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-Derived Suppressor Cells Hinder the Anti-cancer Activity of Immune Checkpoint Inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.674558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T02:16:50Z","timestamp":1699064210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.674558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":55,"alternative-id":["10.3389\/fmolb.2021.674558"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.674558","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"article-number":"674558"}}